Read More Pharma Industry News Will CABOMETYX secure EU approval for advanced neuroendocrine tumors after CHMP’s positive opinion? Ipsen’s CABOMETYX receives EMA's CHMP backing for advanced neuroendocrine tumors; EU approval expected in 2025 following FDA nod. byPallavi MadhirajuJune 24, 2025